Search Results
Results 201 - 250 of 680
< 1 2 3 4 5 6 7 8 9 10 >
Sugiyama A - - 1996
BACKGROUND: Recently, intravenous magnesium therapy has been used for the treatment of ventricular arrhythmias, but data to establish a causal link between the electrophysiological properties and the antiarrhythmic actions are lacking. METHODS AND RESULTS: The acute antiarrhythmic effect of magnesium sulfate was assessed using epinephrine-, digitalis-, and coronary ligation-induced canine ...
Leung D Y - - 1996
Kawasaki Syndrome (KS) is an acute multi-system vasculitis of infancy and early childhood associated with the development of coronary artery abnormalities. The prevalence of cardiovascular abnormalities can be significantly reduced by treating patients during the first 10 days of illness with high-dose intravenous immune globulin (IVIG). Despite the widely held ...
Roth A - - 1996
OBJECTIVE: This study was designed to detect changes in complement levels following acute myocardial infarction and to test whether magnesium sulphate (MgSO4) administration interferes with the complement response that follows acute myocardial infarction. DESIGN: Twenty-nine patients with acute myocardial infarction treated with streptokinase were included and randomly assigned to three ...
Zijlstra F - - 1996
The comparative efficacy of thrombolytic drugs and primary angioplasty for acute myocardial infarction have recently been studied, but long-term follow-up data have not yet been reported. We conducted a randomized trial involving 301 patients with acute myocardial infarction; 152 patients were randomized to primary angioplasty and 149 to intravenous streptokinase. ...
LeDuc T J - - 1996
The use of magnesium sulfate infusion for the management of cardiac dysrhythmia has recently gained popularity. Magnesium sulfate has been advocated for the management of torsade de pointes and other ventricular dysrhythmias. We report the case of a 38-year-old firefighter with atrial tachycardia that was treated unsuccessfully according to Advanced ...
Rubenowitz E - - 1996
The relation between death from acute myocardial infarction and the level of magnesium in drinking water was examined using mortality registers and a case-control design. The study area comprised 17 municipalities in the southern part of Sweden that have different magnesium levels in the drinking water. Cases were men in ...
Salvioni A - - 1996
Procoagulant activity, thrombin and fibrinolytic system activation have been demonstrated in the first 24-48 h after acute myocardial infarction treated with thrombolytic therapy. Little is known about what happens in the subsequent days, during which the incidence of ischaemic recurrence is high. In 21 patients treated with streptokinase and in ...
Sochman J - - 1996
Our previous experimental research and initial clinical observations regarding the use of N-acetylcysteine in the treatment of ischemic and reperfusion injury in acute myocardial infarction gave rise to a study entitled the Infarct Size Limitation: Acute N-acetylcysteine Defense (ISLAND) trial. Today, this randomized, echocardiographically and angiographically controlled study includes the ...
Frandsen N J - - 1996
OBJECTIVE: To determine the time course of platelet alpha granule release in patients with acute myocardial infarction treated with streptokinase. DESIGN: A prospective study. SETTING: Coronary care unit. PATIENTS: Nine with myocardial infarction treated with both streptokinase and aspirin, and nine with acute chest pain but without myocardial infarction, who ...
Khedun S M - - 1996
Ventricular arrhythmia has been postulated as a possible cause of death in young black children who abuse volatile substances, primarily benzine and certain glues that contain n-hexane. A series of protocols were designed to determine the effect of n-hexane on myocardial function and morphology in male laboratory rats. In the ...
Rylander R - - 1996
Magnesium is abundant in nature and the major routes of intake are through food and water. Through changes in the treatment of foodstuffs and altered diets, as well as increased use of surface water with low magnesium content, magnesium deficiency is present in modern society. Magnesium deficiency causes cardiac arrhythmia ...
Baardman T - - 1996
BACKGROUND: The recent international GUSTO trial of 41,021 patients with acute myocardial infarction demonstrated improved 90-min infarct related artery patency as well as reduced mortality in patients treated with an accelerated regimen of tissue plasminogen activator, compared to patients treated with streptokinase. A regimen combining tissue plasminogen activator and streptokinase ...
Mark DB - - 1996
Reperfusion therapy for acute myocardial infarction is one of the most thoroughly studied treatments in all of medicine. The GISSI-1 and ISIS-2 megatrials definitively established the superiority of intravenous streptokinase over conservative care for this condition. Tissue plasminogen activator (t-PA) was introduced with the expectation that it would be substantially ...
Verheugt FW - - 1996
Objective: The medical treatment of failed intravenous streptokinase in patients with acute transmural myocardial infarction using angiographic endpoints. Design: Prospective open angiographic comparison of intracoronary streptokinase with intravenous tissue plasminogen activator. Setting: Single center study in a tertiary institution. Subjects: Eighty-five patients with acute myocardial infarction within 4 hours after ...
Thompson L D - - 1996
A 62-year-old African-American man who underwent coronary artery bypass surgery was found to have repetitive ventricular tachycardia of the "Torsade des pointes" type. The arrhythmia was resistant to bretylium, lidocaine, and pacing, but was controlled by intravenous magnesium sulfate. The recurrent attacks were abolished by a bolus of 1 g ...
Sueta C A - - 1995
Congestive heart failure is characterized by contractile dysfunction and frequent complex ventricular ectopy. Despite advances in therapy, mortality from heart failure is substantial, estimated at 10-80 percent per year, and sudden death is common. Magnesium is the second most common intracellular cation, strongly influences cardiac cell membrane function, and is ...
Bhargava B - - 1995
Intravenous magnesium therapy in acute myocardial infarction (MI) has been shown to be beneficial in many studies. However, these effects are not consistent from one trial to another, and their clinical significance is often questionable. A total of 78 consecutive patients were included in a prospective placebo controlled, randomized study ...
Arstall M A - - 1995
BACKGROUND: N-acetylcysteine (NAC) has been shown to potentiate the effects of nitroglycerin (NTG) and to have antioxidant activity. This is the first study to assess the safety and effect of NAC in the treatment of evolving acute myocardial infarction (AMI). METHODS AND RESULTS: Patients with AMI received either 15 g ...
Christensen C W - - 1995
BACKGROUND: The role of magnesium in treating acute myocardial infarction (AMI) has been controversial. Several small clinical trials indicate that magnesium may have a role in treating AMI early, whereas the other results suggest that magnesium is of questionable benefit. METHODS AND RESULTS: We looked at the effect of magnesium ...
Creamer J D - - 1995
We report a patient who developed a serum sickness-like illness characterized by fever, arthritis, haematuria and a purpuric eruption 7 days following streptokinase therapy for myocardial infarction. Blood tests demonstrated increased circulating immune complexes. The skin involvement resulted in extensive, painful cutaneous infarction with secondary bacterial infection. Serum sickness is ...
Mounsey J P - - 1995
BACKGROUND: In acute myocardial infarction patients who do not reperfuse their infarct arteries shortly after thrombolytic treatment have a high morbidity and mortality. Management of this high risk group remains problematic, especially in centres without access to interventional cardiology. Additional thrombolytic treatment may result in reperfusion and improved left ventricular ...
Lynch M - - 1995
OBJECTIVES: To determine whether patients with acute myocardial infarction undergoing thrombolysis with streptokinase develop changes in renal function. DESIGN: Prospective assessment of renal function in 60 consecutive patients admitted with acute myocardial infarction. SETTING: Tertiary referral centre and city general hospital. PATIENTS: 60 consecutive patients with acute myocardial infarction. Thirty ...
Christensen J H - - 1995
In order to assess the impact of thrombolytic therapy on return to work eighteen months after a first myocardial infarction, 32 patients treated with streptokinase were compared with 30 patients not treated with streptokinase. The study was designed as a historical cohort study. The patients in both groups had continuous ...
Woods K L - - 1995
Clinical management of acute myocardial infarction has been strongly influenced by large, simple trials (mega-trials) with unrestrictive protocols and limited data collection. The design has been adopted to increase statistical power to a maximum. Its validity rests on an effective randomisation procedure and intention-to-treat analysis of deaths. Experience has shown ...
Ogunyankin K O - - 1995
BACKGROUND: Magnesium therapy has been shown to improve survival and decrease the incidence of left ventricular failure when given to patients shortly after a myocardial infarction, but the mechanisms are unknown. We tested the hypothesis that the benefits of magnesium therapy are due to a favorable effect on early left ...
- - 1995
Streptokinase and alteplase are established therapies in acute myocardial infarction. Reteplase is a new thrombolytic agent that can be given as a double bolus. This trial was designed to determine whether the effect of reteplase on survival was at least equivalent (within 1% of fatality rate) to that of a ...
Brügemann J - - 1995
In patients with acute myocardial infarction (MI), quick initiation of thrombolytic therapy is the best strategy for improvement of survival and reduction of morbidity. Streptokinase, a purified product of haemolytic streptococci, is the most commonly administered agent. The compound anistreplase (a complex of streptokinase to plasminogen), is available but currently ...
Lee H S - - 1995
Streptokinase is an antigenic thrombolytic agent used for the treatment of acute myocardial infarction. It reduces mortality as effectively as the nonantigenic alteplase in most infarct patients while having the advantage of being much less expensive. This cost implication is important since myocardial reinfarction is common, with fibrinolytic therapy indicated ...
McGrath K - - 1995
OBJECTIVE: To determine the development of titres of streptokinase (SK) neutralising antibodies after a single dose of SK, to establish when titres decrease to levels at which a second dose might be effective. DESIGN: Analyses of blood samples taken from patients at intervals after SK administration. SETTING: Australian public hospital. ...
Zahger D - - 1995
Thrombolytic therapy in acute myocardial infarction is of established value in recanalizing the occluded coronary artery, reducing infarct size, and decreasing mortality. Here, we review the extensive information provided by large clinical trials on agent and patient selection, timing of treatment, adjuvant therapies, and complications. Early treatment is of prime ...
Gillis J C - - 1995
Alteplase (recombinant tissue-type plasminogen activator) stimulates the fibrinolysis of blood clots by converting plasminogen to plasmin. The efficacy of intravenous alteplase in the early treatment of patients with acute myocardial infarction has been unequivocally proven, and recent results from the GUSTO trial indicate a significant advantage in 30-day survival for ...
Frohna W J - - 1995
A case of iatrogenic, parenteral overdose of magnesium sulfate in a patient with suspected acute myocardial infarction is presented. A 73-year-old man presented with a history and physical examination consistent with suspected acute myocardial infarction and congestive heart failure. During the patient's treatment in the emergency department (ED), the physician ...
Arstall M A - - 1995
We examined the relationship between streptokinase infusion, intensity of myocardial injury and systemic hypotension in patients receiving streptokinase for treatment of evolving acute myocardial infarction. Twenty consecutive patients treated with streptokinase for evolving acute myocardial infarction received continuous blood pressure and S-T segment monitoring of the 12 lead electrocardiogram (ECG) ...
Leor J - - 1995
In conclusion, considering the results from our model, magnesium infusion is effective as adjunct therapy to enhance myocardial salvage in the setting of acute myocardial infarction. However, its effectiveness may be limited to a subset of patients whose magnesium therapy can be started early and combined with early reperfusion therapy.
White H D - - 1995
BACKGROUND: The effects of streptokinase on the occurrence of a combined clinical outcome in patients presenting with recent chest pain and ST depression were investigated in view of the role of thrombus in the pathogenesis of acute ischaemic syndromes. METHODS: 112 patients aged < or = 75 years presenting within ...
Holmes D R DR - - 1995
Thrombolytic therapy remains a mainstay for the treatment of patients with acute myocardial infarction. This therapy has been the subject of intense investigation and multiple studies as well as substantial controversy. Controversial issues include, among others, the specific drug, need for heparin, the relation between time to treatment and outcome ...
Thögersen A M - - 1995
A total of 252 patients with suspected acute myocardial infarction were included in a double blind study and randomised to 50 mmol magnesium sulfate infusion under 20 h or corresponding placebo. Acute myocardial infarction was verified in 117 patients and 59% of these had concomitant treatment with thrombolysis. One-hundred ninety-four ...
Caspi J - - 1995
The effects of perioperative administration of magnesium sulfate on myocardial function was studied in patients with unstable angina (grade IV) undergoing coronary artery bypass grafting. Myocardial protection consisted of antegrade and retrograde continuous warm blood cardioplegia. Patients were randomly divided into two groups. Group A (50 patients) received intravenous magnesium ...
Simes R J - - 1995
BACKGROUND: The Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial was designed to test whether thrombolytic strategies achieving more complete, early, sustained coronary artery patency would lead to further reductions in mortality in patients with acute myocardial infarction. An angiographic substudy within GUSTO-I provided a unique ...
Lareau S - - 1995
The purpose of this review is to look at the role of magnesium in the formation of preservation and reperfusion solutions for the ischaemic heart. Preservation of the heart during cardiac surgery procedures, including cardiac transplantation, can be divided into distinct phases: arrest, cold storage in the case of transplantation, ...
Visser P J - - 1995
The trials reviewed in this study investigated the effect of intravenous magnesium on arrhythmias and mortality in acute myocardial infarction. Nine trials were carried out in the pre-thrombolytic era. They varied in set-up, number of patients, dose of magnesium, follow-up and the type of arrhythmias analyzed. Magnesium reduced mortality in ...
Herzog W R - - 1995
The aim of the present study was to evaluate the relationship between coronary vascular tone and serum magnesium concentration in patients with ischaemic heart disease. Thirty-seven patients were subjected to intracoronary injection of 200 micrograms nitroglycerine after discontinuation of anti-anginal medication for 24 h (group I, n = 23), except ...
Sleight Peter - - 1995
I believe streptokinase is still the trombolytic of choice for the majority of patients with acute myocardial infarction for the following reasons: 1. The superiority of alteplase over streptokinase rests on insecure grounds, statistically (when net clinical benefit is computed for the SK/subcutaneous heparin arm versus the accelerated t-PA arm, ...
Rabbani LE - - 1995
The use of magnesium therapy for acute myocardial infarction remains controversial despite recent clinical trials such as ISIS-4. Magnesium has numerous beneficial effects in the setting of myocardial infarction, including inhibitory effects on platelet aggregation. Clinical trials of magnesium therapy for myocardial infarction have yielded conflicting results that may be ...
Marcus D M - - 1994
We studied a case in which a streptokinase-induced Tenon's hemorrhage developed after retinal detachment surgery. The patient received intravenous streptokinase for myocardial infarction two hours after pars plana vitrectomy and encircling scleral buckling surgery. A Tenon's hemorrhage with an orbital compartment syndrome developed in the patient's left eye, and he ...
Kleiman N S - - 1994
BACKGROUND: A paradoxical increased risk of death has been reported during the first 24 hours after thrombolysis for myocardial infarction. The mechanism of this phenomenon is not known, nor is its relation to the success or failure of reperfusion. The present study was a prospectively designed analysis of deaths occurring ...
Abraham A S - - 1994
Ninety-five patients with acute myocardial infarction were followed up for 6 months to 3 years (mean 25.4 months) in a preliminary study to compare the effects of intravenous magnesium (49 patients) with that of intravenous propranolol (44 patients) given immediately after admission to the intensive care unit. There were four ...
Heesch C M - - 1994
Clinical studies on the use of magnesium in acute myocardial infarction have yielded contradictory results. While the exact reasons for these discrepancies are unclear, it appears that the timing of magnesium administration is crucial to the success or failure of therapy. Although some studies have shown a significant reduction in ...
Herzog W R - - 1994
The effect of magnesium deficiency on postischemic myocardial dysfunction (myocardial stunning) in an open-chest swine model was studied. Twelve swine were assigned either to low magnesium diet or control diet. Myocardial stunning was assessed by measuring regional wall thickening by epicardial Doppler before and after brief occlusion (8 min) of ...
Abraham J S - - 1994
Two patients sustained the rare complication of skin infarction following administration of intravenous streptokinase for acute myocardial infarction. We report evidence that dissolution of thrombus from an unsuspected source and subsequent microembolization of the skin may be responsible for this complication. In patients known to have an aortic aneurysm or ...
< 1 2 3 4 5 6 7 8 9 10 >